Currently, there are 271.77M common shares owned by the public and among those 204.86M shares have been available to trade.
The company’s stock has a 5-day price change of 13.27% and 3.26% over the past three months. ATUS shares are trading -31.69% year to date (YTD), with the 12-month market performance down to -32.32% lower. It has a 12-month low price of $1.52 and touched a high of $3.66 over the same period. ATUS has an average intraday trading volume of 3.51 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 14.97%, 20.64%, and -0.63% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Altice USA Inc (NYSE: ATUS) shares accounts for 46.77% of the company’s 271.77M shares outstanding.
It has a market capitalization of $1.02B and a beta (3y monthly) value of 1.49. The earnings-per-share (ttm) stands at -$0.13. Price movements for the stock have been influenced by the stock’s volatility, which stands at 7.07% over the week and 9.24% over the month.
Earnings per share for the fiscal year are expected to increase by 3.90%, and -30.06% over the next financial year. EPS should shrink at an annualized rate of -0.20% over the next five years, compared to 35.28% over the past 5-year period.
Looking at the support for the ATUS, a number of firms have released research notes about the stock. UBS stated their Neutral rating for the stock in a research note on August 02, 2024, with the firm’s price target at $4-$2. Goldman coverage for the Altice USA Inc (ATUS) stock in a research note released on July 01, 2024 offered a Sell rating with a price target of $2. Exane BNP Paribas on their part issued Underperform rating on April 09, 2024.
